



AMGEN® AMGEN & ANTI-DOPING

FACT SHEET

AMGEN'S POSITION ON DOPING

- Amgen's business is applying biotechnology to discover and deliver important and innovative medicines to treat serious illnesses. Amgen's medicines have helped millions of patients in the fight against cancer, chronic kidney disease and other grievous illnesses. The Company works closely with regulatory agencies and caregivers to make sure that the patients who need them have access to Amgen's medicines and know how to use them safely.
- Amgen is committed to combating inappropriate use of its vital medicines and educating athletes, both amateurs and professionals, of the potential dangers of misusing drugs of any kind.
- Amgen's mission is to serve patients and to discover, develop and deliver innovative medicines to people fighting serious illness. Amgen's medicines are regulated and should only be used by appropriate patients under the supervision of a physician. Amgen strongly opposes any illicit use of its medicines.
- Amgen actively supports the goal of anti-doping agencies around the world to permanently eradicate this pernicious problem from cycling and all professional sports.

WHAT AMGEN IS DOING TO PREVENT DOPING

- Amgen actively promotes healthy lifestyles and discourages doping. The Company produced and distributes a brochure, "Doping Impacts More Than One," to educate athletes, both amateurs and professionals, about the dangers of doping.
- Amgen supports various anti-doping efforts and educational campaigns and over the last decade has collaborated with authorities in the U.S. and globally who oversee testing and sanctioning of athletes. Amgen has also supplied funds to pay for additional out-of-competition testing, funded research labs to develop new and better tests, and supplied medicines free of charge to testing labs to develop new and improved testing procedures.

AMGEN TOUR OF CALIFORNIA

- Amgen has been the title sponsor of the Amgen Tour of California, a professional cycling race, since 2006. Amgen's sponsorship of this event provides a platform for the Company to speak out against abuse of the therapies it makes. Amgen strives to educate the public about the proper use of Amgen's medicines and the medical breakthroughs made possible through biotechnology.
- The Amgen Tour of California has taken a strong, public stance against doping and has been applauded for introducing and enforcing strict anti-doping standards for cyclists participating in the Amgen Tour. AEG, the owner of the Amgen Tour of California, is committed to running a clean race.
- Amgen and AEG have worked with the U.S. Anti-Doping Agency (USADA) to develop and continuously strengthen the Amgen Tour of California's anti-doping program. Anti-Doping protocols for the 2012 Amgen Tour of California have been announced by AEG, owners and presenters of the race. Once again, with the support of the participating teams and riders and as part of the strict and comprehensive programs previously established, Pre-Race Anti-Doping criteria testing will be administered by the US Anti-Doping Agency (USADA) while In-Competition testing will be conducted by the International Cycling Union (UCI) in accordance with the World Anti-Doping Agency (WADA) Code in-competition criteria. These comprehensive standards have been commended by cycling and sports fans concerned with doping in competitive sports and are the strictest standards of any competitive cycling event.

COMPREHENSIVE ANTI-DOPING PROTOCOLS 2012 AMGEN TOUR OF CALIFORNIA

The 2012 program for riders will include the following components:

Pre- Race Testing and Protocols:

- USADA will conduct no-advance notice, out-of-competition sample collections during the period of time leading up to the start of the race on riders under USADA's jurisdiction.
- All riders will be subject to either urine and/or blood testing.
- Samples will be tested for the substances and methods included on the WADA Prohibited List, such as steroids, hormones (e.g. EPO), stimulants and various masking agents and could be subject to special analysis such as CIR and testing for CERA and hGH. For a full list of the substances and methods listed on the WADA Prohibited List please visit, www.usada.org/prohibited-list/.
- All participants must be in a registered testing pool leading up to the race, including the provision of whereabouts information, informing and updating as to details of their whereabouts so they may be located for testing at any location and at any time, without advance notice.
- Athletes who are not already in a registered testing pool will be required to take mandatory education programming, including comprehensive information on the anti-doping rules and responsibilities, as well as information on the merits and benefits of clean competition.
- Additional education programming opportunities will be made accessible to all riders, teams and support personnel to ensure maximum understanding of the specific anti-doping rules.

In-Competition Testing and Protocols

Testing will be conducted throughout the Amgen Tour of California by the UCI in accordance with the WADA Code in-competition criteria. This will include daily doping controls following a strategic test distribution plan. After each stage the following riders will be tested:

- The winner of each stage will be tested.
- The leader in the General Classification will be tested.
- At least two random athletes will be tested.
- Additional riders may be subject to blood or urine testing after each stage.
- Samples may be tested for the substances and methods included on the WADA Prohibited List, including EPO. AEG has additionally requested and will pay for EPO testing on all samples for in-competition testing. For a full list of the substances and methods listed on the WADA Prohibited List please visit, www.usada.org/prohibited-list/.

For more information on Amgen's position on doping, please contact:

Mary Klem, Director
Amgen Corporate Communications
mklem@amgen.com
805-447-6979 (USA)